01.04.2015 | Editorial
Biosimilar Versus Generic Drugs: Same But Different?
Erschienen in: Applied Health Economics and Health Policy | Ausgabe 2/2015
Einloggen, um Zugang zu erhaltenExcerpt
Research and development characterizes the pharmaceutical industry, and the flow of new drugs is protected by patents to remunerate this investment. Once a patent expires, price competition is possible, since any manufacturer can copy the originator product. This circumstance justifies the place in the pharmaceutical market for generics and biosimilars, i.e. off-patent medicines to be sold at lower prices than their originators. …Anzeige